Clinical trial
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With…
NCT00403546 · Donald C. Goff, MD, Other · Completed
Key facts
| NCT number | NCT00403546 |
|---|---|
| Title | High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms |
| Official title | High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms |
| Acronym | HDZ |
| Lead sponsor | Donald C. Goff, MD, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Ziprasidone 80-160 mg/d, Placebo, Ziprasidone 160 mg/d |
| Enrollment | 131 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Nov 23, 2006 |
| Last update posted | Jun 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: